Literature DB >> 9521425

Evaluation of locus heterogeneity and EXT1 mutations in 34 families with hereditary multiple exostoses.

W H Raskind1, E U Conrad, M Matsushita, E M Wijsman, D E Wells, N Chapman, L J Sandell, M Wagner, J Houck.   

Abstract

Hereditary multiple exostoses (EXT) is an autosomal dominant disorder characterized by growth of benign bone tumors. Three chromosomal loci have been implicated in this genetically heterogeneous disease: EXT1 at 8q24, EXT2 at 11p13, and EXT3 on 19p. EXT1 and EXT2 were recently cloned. We evaluated 34 families with EXT to estimate the proportion of disease attributable to EXT1, EXT2, and EXT3 and to investigate the spectrum of EXT1 mutations. Linkage analyses combined with heterogeneity testing provides strong evidence in favor of linkage of disease to both chromosomes 8 and 11, but does not support evidence of linkage to chromosome 19 in this data set. The 11 EXT1 exons were PCR-amplified and sequenced in all 11 isolated cases and in 20 of the 23 familial cases. Twelve different novel EXT1 mutations were detected, including 5 frame-shift deletions or insertions, 1 codon deletion, and 6 single base-pair substitutions distributed across 8 of the exons. Only 2 of the mutations were detected in more than one family. Three mutations affect sites in which alterations were previously reported. Nonchain-terminating missense mutations were identified in codons 280 and 340, both coding for conserved arginine residues. These residues may be crucial to the function of this protein. Although the prevalence of EXT has been estimated to be approximately 1/50,000 individuals, the disease has been reported to occur much more frequently in the Chamorro natives on Guam. Our detection of an EXT1 mutation in one Chamorro subject will allow investigation of a possible founder effect in this population. Combined mutational and heterogeneity analyses in this set of families with multiple exostoses suggest that 66% of our total sample, including 45% of isolated and 77% of familial cases, are attributable to abnormalities in EXT1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521425     DOI: 10.1002/(SICI)1098-1004(1998)11:3<231::AID-HUMU8>3.0.CO;2-K

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

1.  The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.

Authors:  C McCormick; G Duncan; K T Goutsos; F Tufaro
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Genetic analysis of hereditary multiple exostoses in Tunisian families: a novel frame-shift mutation in the EXT1 gene.

Authors:  Sana Sfar; Abderrazak Abid; Wijden Mahfoudh; Houyem Ouragini; Farah Ouechtati; Sonia Abdelhak; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2008-03-11       Impact factor: 2.316

3.  Involvement of Ext1 and heparanase in migration of mouse FBJ osteosarcoma cells.

Authors:  Yinan Wang; XiaoYan Yang; Sadako Yamagata; Tatsuya Yamagata; Toshinori Sato
Journal:  Mol Cell Biochem       Date:  2012-10-10       Impact factor: 3.396

4.  EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas.

Authors:  J V Bovée; A M Cleton-Jansen; W Wuyts; G Caethoven; A H Taminiau; E Bakker; W Van Hul; C J Cornelisse; P C Hogendoorn
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

5.  Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.

Authors:  P K Cheung; C McCormick; B E Crawford; J D Esko; F Tufaro; G Duncan
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

6.  A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.

Authors:  Kevin B Jones; Virginia Piombo; Charles Searby; Gail Kurriger; Baoli Yang; Florian Grabellus; Peter J Roughley; Jose A Morcuende; Joseph A Buckwalter; Mario R Capecchi; Andrea Vortkamp; Val C Sheffield
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

7.  Malignant progression in two children with multiple osteochondromas.

Authors:  Gregory A Schmale; Douglas S Hawkins; Joe Rutledge; Ernest U Conrad
Journal:  Sarcoma       Date:  2010-05-09

8.  Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management.

Authors:  Liesbeth Hameetman; Judith Vmg Bovée; Antonie Hm Taminiau; Herman M Kroon; Pancras Cw Hogendoorn
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

9.  Mutation screening of EXT1 and EXT2 by denaturing high-performance liquid chromatography, direct sequencing analysis, fluorescence in situ hybridization, and a new multiplex ligation-dependent probe amplification probe set in patients with multiple osteochondromas.

Authors:  Ivy Jennes; Mark M Entius; Els Van Hul; Alessandro Parra; Luca Sangiorgi; Wim Wuyts
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

10.  Assessing the general population frequency of rare coding variants in the EXT1 and EXT2 genes previously implicated in hereditary multiple exostoses.

Authors:  Diana L Cousminer; Alexandre Arkader; Benjamin F Voight; Maurizio Pacifici; Struan F A Grant
Journal:  Bone       Date:  2016-09-09       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.